Global Biopharmaceutical CMO Market – Analysis By Product Type (Microbial, Others), By Region, By Country (2020 Edition): Opportunities and Forecast (2020-2025) - By Region (N. America, Europe, APAC), By Country (US, Germany, Switzerland, Denmark, China, Japan, South Korea)

Report ID: AA-90404923 | Publihed: 31-Mar-2020 | No of Pages: 130


USD 3995
USD 5795


Publish Date:


Total pages:


Executive Summary

Global Biopharmaceutical CMO Market was valued at USD 13296.29 million in the year 2019. Escalating number of patients suffering from various diseases with growing investment in the healthcare industry by government in major economies and increasing awareness among consumers regarding impact of various viruses on health, has been anticipated to infuse growth in the market for Biopharmaceutical CMO during the forecasting period of 2020-2025.

Under the product segment, Others is anticipated to witness a substantial market share owing to growing partnership among various pharmaceutical companies and leading CMOs which are helping in providing medicines, biologics delivery with advanced technology and efficient labour force backed with enhanced investment in expanding geographically, will be accelerating the Biopharmaceutical CMO market growth in the coming years.
Among the regions, Europe, followed by North America and Asia Pacific, will experience remarkable market share owing to presence of major countries including United Kingdom, Norway, Denmark, Switzerland that feature efficient healthcare system supported by ever growing number of patients. Rising need of developing medicine for many viruses coupled with growing mergers and acquisitions in the region between pharma companies and CMOs, will be propelling the Biopharmaceutical CMO market growth during the period of 2020-2025.

Scope of the Report

• The report analyses Biopharmaceutical CMO market By Value.
• The report analyses Biopharmaceutical CMO Market By Product Type (Microbial, and Others).
• The Global Biopharmaceutical CMO Market has been analysed By Region (North America, Europe, and Asia Pacific) and By Country (United States, Germany, Switzerland, Denmark, China, Japan, South Korea).
• The key insights of the report have been presented through the frameworks of Major mergers and acquisitions. Also, the attractiveness of the market has been presented By Region, and By Product Type. Additionally, the major opportunities, SWOT analysis, trends, drivers and challenges of the industry has been analysed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Wuxi Biologics, Boehringer Ingelheim, Lonza, Samsung Biologics.
• The report presents the analysis of Biopharmaceutical CMO market for the historical period of 2015-2019 and the forecast period of 2020-2025.

Key Target Audience

• Biopharmaceutical CMO Vendors
• Pharmaceutical Companies
• Pharmaceutical Manufacturers
• Consulting and Advisory Firms
• Investment Banks and Equity Firms

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.